ESC 2008: "Real-world" study backs Biosensors' DES
This article was originally published in Clinica
Executive Summary
BioMatrix, the drug-eluting stent (DES) developed by Biosensors, has matched the efficacy of rival device Cypher, in a non-inferiority trial described by the firm's president as "risky".
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.